glp 1 agonist action Frontiers Possible mechanisms of action of
Description
Nystrm T, Gonon AT, Sjholm A, Pernow J
V., & Elisaf, M
Oral semaglutide showed superiority over placebo [35], empagliflozin [36], and sitagliptin [37] and noninferiority over liraglutide [38] in reducing HbA1c levels in T2DM patients
The rising prevalence of type 2 diabetes worldwide is driving the GLP-1 development
N Engl J Med 387(3):205216 Cesta CE, Rotem R, Bateman BT et al (2024) Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy
